Get the Stockscreener App
3.14
3.63%
0.11
After Hours:
3.17
0.03
+0.96%
Dermata Therapeutics Inc stock is traded at $3.14, with a volume of 8,575.
It is up +3.63% in the last 24 hours and down -16.49% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$3.03
Open:
$3.03
24h Volume:
8,575
Relative Volume:
0.07
Market Cap:
$3.22M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.1466
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
+20.77%
1M Performance:
-16.49%
6M Performance:
-56.99%
1Y Performance:
-71.45%
1-Day Range:
$3.03
$3.14
1-Week Range:
$2.53
$3.14
52-Week Range:
$2.36
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
3.14 | 3.11M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Returns Recap: Will Dermata Therapeutics Inc. stock see insider buyingWeekly Trade Review & Detailed Earnings Play Strategies - moha.gov.vn
Is Dermata Therapeutics Inc. stock a contrarian buyJuly 2025 Reactions & Entry Point Confirmation Signals - moha.gov.vn
Dermata Therapeutics Inc files for mixed shelf of up to $100 million - MarketScreener
Dermata Therapeutics, Inc.Warrant (NQ: DRMAW - Markets Financial Content
What momentum indicators show for Dermata Therapeutics Inc. Equity Warrant stockStock Surge & Real-Time Market Sentiment Alerts - newser.com
Can Dermata Therapeutics Inc. stock deliver surprise earnings beatJuly 2025 Snapshot & Stepwise Entry/Exit Trade Alerts - newser.com
Dermata Therapeutics Ends License Agreement with Villani - MSN
Can Dermata Therapeutics Inc. Equity Warrant stock sustain market leadershipTrend Reversal & Trade Opportunity Analysis - newser.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Statistical indicators supporting Dermata Therapeutics Inc.’s strengthEarnings Overview Summary & Real-Time Market Sentiment Reports - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock a safe investment in uncertain marketsWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
Is Dermata Therapeutics Inc. Equity Warrant stock vulnerable to regulatory risksJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - newser.com
Why Dermata Therapeutics Inc. stock could see breakout soonWeekly Investment Summary & Stock Market Timing Techniques - newser.com
Can Dermata Therapeutics Inc. stock sustain market leadershipJuly 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - newser.com
How to manage a losing position in Dermata Therapeutics Inc.July 2025 Market Mood & Weekly Setup with High ROI Potential - newser.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Will Dermata Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Review & Low Drawdown Investment Ideas - newser.com
How to use Fibonacci retracement on Dermata Therapeutics Inc.Dollar Strength & Real-Time Buy Signal Alerts - newser.com
Can Dermata Therapeutics Inc. Equity Warrant stock resist market sell offsJuly 2025 Price Swings & Breakout Confirmation Alerts - newser.com
Is Dermata Therapeutics Inc. Equity Warrant building a consolidation base2025 Fundamental Recap & Short-Term High Return Strategies - newser.com
Has Dermata Therapeutics Inc. formed a bullish divergenceMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Dermata Therapeutics Incon Nov 17, Termina - 富途牛牛
Visualizing Dermata Therapeutics Inc. stock with heatmapsShare Buyback & Step-by-Step Trade Execution Guides - newser.com
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Chronicle-Tribune
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):